Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA).
Priscila Hermont Goncalves
No relevant relationships to disclose
Joshua Michael Ruch
No relevant relationships to disclose
Jennifer Byer
No relevant relationships to disclose
Anthony Frank Shields
No relevant relationships to disclose
Minsig Choi
No relevant relationships to disclose
Richard D. Kim
No relevant relationships to disclose
Mark M. Zalupski
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi